Yulia Slavina

Biologics may shift outcomes in tendon injuries, Anika Therapeutics explores

Biologics may shift outcomes in tendon injuries, Anika Therapeutics explores
Anika Therapeutics explores tendon innovation

Anika Therapeutics is focusing on the potential for biologic scaffolds to reduce failure rates in tendon repair procedures. Dr. Timothy Codd, featured on The Ortho Show, analyzes why biologics could support the body’s own healing process over standard approaches.

The discussion underscores growing momentum in orthobiologics as researchers look for ways to improve patient outcomes in orthopedic surgery. Industry stakeholders are closely watching the integration of innovative biologic materials into clinical practice.

Anika has previously launched Hyaff, a proprietary hyaluronic acid derivative developed for regenerative tendon and cartilage repair, according to an earlier announcement. The company has also introduced Cingal as the only approved combination therapy of hyaluronic acid and corticosteroid for osteoarthritis pain, though it remains unavailable in the U.S. These efforts highlight Anika's focus on advanced materials for orthopedic applications.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.